Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 3/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1547051 | 0.98 | CXCR4 (0.46) | CXCR4SIGMAR1POLBSMN1; SMN2NMT1 | |
| Hydrochloric Acid SCHEMBL15735731 | 0.98 | CXCR4 (0.46) | CXCR4SIGMAR1POLBSMN1; SMN2NMT1 | |
| SCHEMBL616071 | 0.88 | POLB (0.42) | CXCR4SIGMAR1POLBSMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL1155904 | 0.86 | POLB (0.41) | CXCR4SIGMAR1POLBSMN1; SMN2KDM4E | |
| Piperazine SCHEMBL28245279 | 0.86 | CXCR4 (0.44) | CXCR4SIGMAR1POLBSMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL309825 | 0.86 | POLB (0.41) | CXCR4SIGMAR1POLBSMN1; SMN2KDM4E | |
| SCHEMBL4369887 | 0.82 | CXCR4 (0.46) | CXCR4SIGMAR1POLBSMN1; SMN2NMT1 | |
| SCHEMBL8812204 | 0.81 | HRH3 (0.48) | SMN1; SMN2CHRM2CHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL1546950 | 0.81 | CXCR4 (0.44) | CXCR4SIGMAR1POLBSMN1; SMN2NMT1 | |
| SCHEMBL2007988 | 0.81 | CXCR4 (0.53) | CXCR4SIGMAR1POLBSMN1; SMN2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104710408-A | Chiral cis-imidazolines | HOFFMANN LA ROCHE | 2015-06-17 | — | — | CN | disclosed |
| EP-1960368-B1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | HOFFMANN LA ROCHE (CH) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014082889-A1 | NOVEL IMIDAZOLINES AS DUAL INHIBITORS OF MDM2 AND MDMX | F. HOFFMANN-LA ROCHE AG (CH) | 2014-06-05 | — | — | WO | disclosed |
| US-20140148443-A1 | Novel Imidazolines as dual inhibitors of MDM2 and MDMX | HOFFMANN-LA ROCHE INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8513239-B2 | Chiral cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2536731-A1 | SUBSTITUTED SPIROINDOLINONES | F. Hoffmann-La Roche AG (CH) | 2012-12-26 | — | — | EP | disclosed |
| EP-2203437-B1 | CHIRAL CIS-IMIDAZOLINES | HOFFMANN LA ROCHE (CH) | 2012-11-07 | — | — | EP | disclosed |
| US-8288431-B2 | Substituted spiroindolinones | HOFFMANN-LA ROCHE INC. (US) | 2012-10-16 | — | — | US | disclosed |
| WO-2011101297-A1 | SUBSTITUTED SPIROINDOLINONES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-25 | — | — | WO | disclosed |
| US-20110201635-A1 | SUBSTITUTED SPIROINDOLINONES | LIU JIN-JUN | 2011-08-18 | — | — | US | disclosed |
| WO-2007104714-A1 | SPIROINDOLINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-20 | — | — | WO | disclosed |
| US-20070129416-A1 | 4,4,5,5, Tetrasubstituted imidazolines | DING QINGJIE | 2007-06-07 | — | — | US | disclosed |
| WO-2007063013-A1 | 2,4,5-TRIPHENYL IMIDAZOLINE DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN P53 AND MDM2 PROTEINS FOR USE AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | WO | disclosed |
| EP-1753727-A1 | NOVEL CIS-IMIDAZOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-21 | — | — | EP | disclosed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| WO-2006097261-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES AND THEIR USE AS ANTI-CANCER MEDICAMENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-09-21 | — | — | WO | disclosed |
| US-20060211693-A1 | Cis-imidazolines | FOTOUHI NADER | 2006-09-21 | — | — | US | disclosed |
| US-20050288287-A1 | Chiral cis-imidazolines | FOTOUHI NADER | 2005-12-29 | — | — | US | disclosed |
| WO-2005110996-A1 | NOVEL CIS-IMIDAZOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005110996-A1 | NOVEL CIS-IMIDAZOLINES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211693-A1 | Cis-imidazolines | TP53, MDM2, CDC25C | CXCR4 455/4885SIGMAR1 3877/4885POLB 1881/4885 |
| US-20110201635-A1 | SUBSTITUTED SPIROINDOLINONES | CCNY, XPOT, FOXK1 | CXCR4 790/4885SIGMAR1 724/4885POLB 2405/4885 |
| US-20070129416-A1 | 4,4,5,5, Tetrasubstituted imidazolines | RPS4X, RPS4Y1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CXCR4 22/4885SIGMAR1 1615/4885POLB 4301/4885 |
| US-20140148443-A1 | Novel Imidazolines as dual inhibitors of MDM2 and MDMX | MDM2, MDM4, TP53 | CXCR4 551/4885SIGMAR1 3779/4885POLB 3529/4885 |
| US-20050288287-A1 | Chiral cis-imidazolines | TP53, MDM2, TP53BP1 | CXCR4 79/4885SIGMAR1 2590/4885POLB 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.